Arecor Therapeutics (LON:AREC) Hits New 1-Year Low – Should You Sell?

Shares of Arecor Therapeutics plc (LON:ARECGet Free Report) hit a new 52-week low on Wednesday . The stock traded as low as GBX 48 ($0.62) and last traded at GBX 48 ($0.62), with a volume of 11 shares trading hands. The stock had previously closed at GBX 49.50 ($0.64).

Arecor Therapeutics Stock Up 0.7 %

The firm has a market capitalization of £18.63 million, a PE ratio of -1.74 and a beta of -0.18. The firm’s 50 day moving average price is GBX 53.77 and its two-hundred day moving average price is GBX 66.37. The company has a quick ratio of 6.24, a current ratio of 1.37 and a debt-to-equity ratio of 5.51.

About Arecor Therapeutics

(Get Free Report)

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.

See Also

Receive News & Ratings for Arecor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arecor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.